Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine sulfate for idiopathic membranous nephropathy
ChiCTR1900021757Phase 4Recruiting
- Sponsor
- Army Medical University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in idiopathic membranous glomerulonephritis (IMG) (4 arms), sponsored by Army Medical University. Primary endpoint: Complete remission rate at 48 weeks. Started Mar 2019; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR1900021757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021757.